Product
Ceftobiprole
Aliases
Ceftobiprole medocaril
4 clinical trials
6 indications
Indication
Neonatal SepsisIndication
Bacterial InfectionsIndication
Chronic Kidney DiseaseIndication
Liver InsufficiencyIndication
Immune suppressionIndication
Staphylococcus aureus bacteremiaClinical trial
A Multicenter, Open-label, Single-arm, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Ceftobiprole Medocaril in Term and Pre-term Neonates and Infants up to 3 Months of Age With Late-onset SepsisStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-label Study to Evaluate the Single-dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment With Systemic AntibioticsStatus: Terminated, Estimated PCD: 2020-02-25
Clinical trial
Retrospective Chart Review to Evaluate the Safety Profile of Ceftobiprole in Patients With Impaired Hepatic or Renal Function or ImmunosuppressionStatus: Completed, Estimated PCD: 2023-06-09
Clinical trial
A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective EndocarditisStatus: Completed, Estimated PCD: 2022-03-11